D. Boral Capital Lowers VolitionRx (NYSE:VNRX) Price Target to $3.00

VolitionRx (NYSE:VNRX) had its price target reduced by equities research analysts at D. Boral Capital from $5.00 to $3.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Several other research analysts have also recently issued reports on VNRX. HC Wainwright decreased their price target on VolitionRx from $2.50 to $1.50 and set a “buy” rating for the company in a research note on Monday, November 17th. Maxim Group lowered shares of VolitionRx from a “buy” rating to a “hold” rating in a research report on Wednesday, December 3rd. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, VolitionRx currently has a consensus rating of “Buy” and a consensus price target of $2.50.

VolitionRx Trading Up 10.3%

Shares of NYSE VNRX opened at $0.27 on Thursday. VolitionRx has a 12-month low of $0.23 and a 12-month high of $0.94. The company has a market cap of $32.80 million, a PE ratio of -0.74 and a beta of 1.26. The stock has a 50 day simple moving average of $0.37 and a 200-day simple moving average of $0.56.

Insider Activity at VolitionRx

In other VolitionRx news, Director Guy Archibald Innes acquired 96,153 shares of the stock in a transaction dated Tuesday, October 14th. The shares were bought at an average price of $0.51 per share, with a total value of $49,038.03. Following the purchase, the director directly owned 1,062,967 shares of the company’s stock, valued at approximately $542,113.17. This trade represents a 9.95% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Cameron John Reynolds bought 110,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 14th. The shares were acquired at an average cost of $0.51 per share, with a total value of $56,100.00. Following the completion of the purchase, the chief executive officer owned 2,534,847 shares of the company’s stock, valued at approximately $1,292,771.97. The trade was a 4.54% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 274,229 shares of company stock worth $136,657 in the last ninety days. Corporate insiders own 10.40% of the company’s stock.

Institutional Investors Weigh In On VolitionRx

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Blair William & Co. IL purchased a new stake in shares of VolitionRx during the second quarter valued at $30,000. Virtu Financial LLC purchased a new stake in VolitionRx during the third quarter valued at about $28,000. Northwestern Mutual Wealth Management Co. acquired a new position in shares of VolitionRx in the second quarter worth about $52,000. Silverberg Bernstein Capital Management LLC increased its position in shares of VolitionRx by 42.8% in the second quarter. Silverberg Bernstein Capital Management LLC now owns 200,782 shares of the company’s stock worth $153,000 after acquiring an additional 60,209 shares in the last quarter. Finally, Citadel Advisors LLC lifted its position in shares of VolitionRx by 70.1% in the 3rd quarter. Citadel Advisors LLC now owns 329,520 shares of the company’s stock valued at $224,000 after acquiring an additional 135,775 shares in the last quarter. 8.09% of the stock is owned by institutional investors and hedge funds.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.